Australia markets closed

Armata Pharmaceuticals, Inc. (ARMP)

NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
2.5950+0.1050 (+4.22%)
As of 12:09PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close2.4900
Open2.5000
Bid2.5000 x 1000
Ask2.7100 x 900
Day's range2.4400 - 2.6500
52-week range1.0700 - 5.2600
Volume5,654
Avg. volume15,935
Market cap93.8M
Beta (5Y monthly)0.70
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • PR Newswire

    Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update

    Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its fourth quarter and full-year ended December 31, 2023, and provided a corporate update.

  • PR Newswire

    Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

    Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross proceeds to be received by the C

  • PR Newswire

    Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit

    Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Mina Pastagia, M.D., Chief Medical Officer, will deliver a presentation at the 6th Annual Bacteriophage Therapy Summit, which is being held February 27-29 in Boston.